Nkarta, Inc. NKTX
We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. Our lead pipeline program is NKX019, a chimeric antigen receptor-natural killer ("CAR NK") product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases. Our CAR NK platform enables an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. We have developed proprietary technologies designed to generate an abundant supply of NK cells, increase NK cell recognition of target antigens, and enhance NK cell fitness to support scalable, off the shelf administration. NKX019 is allogeneic, which means it is produced using cells from a different person than the patient(s) being treated, and it is produced in quantity, then frozen and therefore available for treating patients without delay, unlike autologous cell therapies, which are derived from a patient's own cells and must be manufactured as needed for each patient. We believe that engineered NK cells have the potential to be effective and accessible therapies for autoimmune diseases and other diseases, be well tolerated, and avoid some of the toxicities observed with other cell therapies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | $115.0K | — |
| R&D | $90.4M | $96.7M | $96.8M | $90.9M | $63.4M | $36.2M | $17.2M | — |
| SG&A | $31.6M | $31.4M | $34.9M | $28.1M | $23.0M | $15.3M | $5.2M | — |
| Total operating expenses | $122.0M | $128.2M | $131.7M | $119.0M | $86.4M | $51.5M | $22.5M | — |
| Operating income | -$122.0M | -$128.2M | -$131.7M | -$119.0M | -$86.4M | -$51.5M | -$22.3M | — |
| Pre-tax income | -$104.1M | -$108.8M | -$117.5M | -$113.8M | -$86.1M | -$91.4M | -$21.1M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$104.1M | -$108.8M | -$117.5M | -$113.8M | -$86.1M | -$91.4M | -$21.1M | — |
| EPS, basic | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | — | — | — |
| EPS, diluted | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -5.44 | -14.41 | — |
| Shares, diluted (wtd. avg.) | 74.0M | 67.9M | 49.0M | 43.6M | 32.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $39.6M | $27.9M | $31.0M | $37.5M | $60.8M | $96.7M | $20.6M | — |
| Short-term investments | $236.6M | $239.5M | $217.1M | $314.6M | $177.3M | $218.2M | $16.4M | — |
| Total current assets | $282.5M | $273.3M | $253.1M | $360.7M | $245.8M | $318.8M | $37.5M | — |
| Property, plant and equipment | $66.7M | $74.7M | $79.3M | $61.9M | $12.9M | $9.3M | $3.1M | — |
| Total assets | $404.2M | $501.2M | $378.9M | $472.9M | $273.9M | $337.6M | $48.4M | — |
| Accounts payable | $2.1M | $638.0K | $3.7M | $1.8M | $1.1M | $1.2M | $1.9M | — |
| Total current liabilities | $22.3M | $18.9M | $23.3M | $22.0M | $12.9M | $8.8M | $8.2M | — |
| Total liabilities | $91.9M | $93.2M | $105.6M | $100.7M | $22.9M | $16.4M | $14.1M | — |
| Retained earnings | -$648.3M | -$544.2M | -$435.4M | -$317.9M | -$204.1M | -$118.0M | -$26.7M | — |
| Total equity | $312.3M | $408.0M | $273.3M | $372.2M | $251.0M | $321.2M | -$25.5M | -$5.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$88.7M | -$99.7M | -$86.2M | -$57.0M | -$67.9M | -$43.5M | -$18.4M | — |
| Depreciation and amortisation | $9.2M | $9.2M | $5.9M | $2.6M | $1.8M | $800.0K | $400.0K | — |
| Stock-based compensation | $8.6M | $16.7M | $17.2M | $16.9M | $14.5M | $6.7M | $947.0K | — |
| Capital expenditure | $1.2M | $4.4M | $28.1M | $47.1M | $5.0M | $7.5M | $1.9M | — |
| Investing cash flow | $100.3M | -$129.6M | $79.0M | -$184.7M | $32.5M | -$210.1M | -$18.3M | — |
| Financing cash flow | $141.0K | $226.1M | $691.0K | $219.0M | $1.2M | $329.8M | $49.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016403.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $115.0K | — | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$21.1M | -$91.4M | -$86.1M | -$113.8M | -$117.5M | -$108.8M | -$104.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |